Tech Company Financing Transactions

Graphite Bio Funding Round

Versant Ventures and Samsara BioCapital participated in a $45 million Series A funding round for Graphite Bio. The financing round closed on 9/17/2020.

Transaction Overview

Company Information

Company Status

Publicly-held

Industry

Biopharmaceutical

Mailing Address

279 E. Grand Ave. 430
San Francisco, CA 94025
USA

Phone

Undisclosed

Website

www.graphitebio.com

Email Address

[email protected]

Overview

Graphite Bio is a next-generation gene editing company focused on targeted DNA integration to precisely insert genetic payloads to treat a broad range of severe diseases. The company was co-founded by academic pioneers in the fields of gene editing and gene therapy, and is backed by Versant Ventures and Samsara BioCapital.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Josh Lehrer

        

Chief Operating Officer

Katherine Stultz

        

VP - Bus. Development

Philip Gutry

        

Browse more venture capital transactions:

Prev: 9/17/2020: Air venture capital transaction
Next: 9/17/2020: Stemson Therapeutics venture capital transaction

Share this article

About Our VC Transactions Data

We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary